Court Orders Unsealing of Damaging Documents in Abacus Litigation
ABX has more than doubled off its 52-week low of $5 on light trading volume (0.2× avg).
Summary
A U.S. court has ordered the unsealing of key documents in the Coventry-Abacus litigation, revealing serious allegations about Abacus's life expectancy estimates and valuation practices. The unsealed documents show that Lapetus, a life expectancy provider, had an actual-to-expected ratio of just 41.5%, and that Lewis & Ellis used a lower discount rate than Abacus's own. Additionally, Abacus allegedly failed to disclose its use of internal life expectancy estimates for over one-third of policies. These revelations could undermine confidence in Abacus's actuarial assumptions and financial reporting, potentially exposing the company to legal and reputational damage. With a market cap of over $1 billion, the litigation risk is material. The next steps in the case will be closely watched for further disclosures or settlements.
At the time of this announcement, ABX was trading at $10.79 on NYSE in the Finance sector, with a market capitalization of approximately $1B. The 52-week trading range was $5.00 to $12.44. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.